

# 1. CONSOLIDATED QUARTERLY FINANCIAL RESULTS (APRIL 1, 2003 – JUNE 30, 2003)

## 1. NOTES TO PREPARATION OF THE QUARTERLY FINANCIAL REPORT

- (1) There have been no changes in accounting methods used by the Company during the quarterly period.
- (2) There have been no changes in the number of consolidated subsidiaries and associated companies accounted for by the equity method.

## 2. QUARTERLY FINANCIAL RESULTS

### (1) RESULTS OF QUARTERLY OPERATIONS

Period	Net Sales	Percent Change	Operating Income	Percent Change	Ordinary Income	Percent Change
--------	-----------	----------------	------------------	----------------	-----------------	----------------

April 1, 2003-

**(REFERENCE DATA 1)**  
**NON-CONSOLIDATED RESULTS OF QUARTERLY OPERATIONS**

Period	Net Sales	Operating Income	Ordinary Income
--------	-----------	---------------------	--------------------

---

All figures less than 1,000,000 yen have been omitted.

## [Current Quarter Summary Highlights]

Consolidated sales results came to ¥116,649 million which was a 1.3% increase compared to the corresponding period of last year. With respect to individual markets, the North American and European markets continued growing; however, the market in Japan remained in a harsh operating environment due to a protracted economic slowdown, and measures to restrain increases in health care costs have been implemented, such as the National Health Insurance (NHI) price revision in April of this year.

Regarding the net sales of main products, sales of *Aricept*, an Alzheimer's disease treatment, surged 27.8% from the previous year, to ¥32,472 million. Sales of *Aciphex/Pariet*, a proton pump inhibitor, decreased 4.7% to ¥26,260 due to currency exchange factors as well as a price change (local currency basis) announced in the 4th Quarter that yielded increased demand for that quarter. Sales on a local currency basis in the 1st Quarter slightly increased.

With respect to expenses, aggressive research and development resulted in an increase of 25.0% to ¥16,896 million; selling, general and administrative expenses came to ¥57,713 million which was an increase of 5.6%; costs of goods sold came to ¥22,843 and was a ¥5,040 million reduction from the previous year period. The sales cost ratio was 19.6% and was a 4.6% improvement from the previous year period.

As a result, operating income was ¥19,078 million, a 0.3% increase; ordinary income came to ¥19,571 million, a 6.7% increase; and net income came to ¥12,335 million, a 10.3% increase.

Earnings per share came to ¥42.28 which was a ¥3.95 yen increase from the corresponding period last year.

Average exchange rates for the quarter were: ¥118.50/U.S.\$ and ¥134.66/Euro (1st Quarter 2002 Exchange rates were: ¥127.04/U.S.\$ and ¥116.57/Euro)

[Results by segment]

(Net sales for each segment are net sales to external customers.)

(1) Performance by operating segment

Pharmaceuticals segment

The sales of *Aricept* in Japan, North America, and Europe registered growth while the sales of *Aciphex/Pariet* remained strong in Japan and Europe. Consequently, sales increased 2.9% to ¥111,223 million; however, operating income in the segment came to ¥19,381 million showing a slight increase of 0.6% due to increases in the expenses associated with clinical development and business development in the neurology therapeutic area.

Other segments

Sales in other segments came to ¥5,425 million yen, a decline of 23.4% over the previous year period, and operating income rose 21.9% to ¥368 million.

(2) Performance by geographic area

Japan: Sales in Japan amounted to ¥63,713 million, down 4.6%, and operating income came to ¥20,100 million, down 4.1%. Sales of *Aricept* was ¥6,971 million and *Pariet* sales came to ¥1,736 million; however, reduced sales in other pharmaceuticals, certain consumer health care products, as well as the transfer of the animal health business among others resulted in decreased sales and income in comparison to the previous year period.

North America: Sales in North America climbed 8.0% to ¥42,258 million and operating income increased 157.5% to ¥1,294 million. Sales of *Aricept* amounted to ¥19,140 million, an increase of 29.5%, and sales of *Pariet* came to ¥22,606 million, a decline of 6.3%.

Europe Sales in Europe grew 26.2%, to ¥8,505 million while operating income decreased 2.7% to ¥547 million. Sales of *Aricept* amounted to ¥5,767 million, on increase of 26.4% and sales of *Pariet* totaled ¥1,581 million, an increase of 3.2%.

Asia and other regions

Due to the strength of the Japanese yen to many Asian currencies in comparison to the previous year period, sales decreased 6.7% to ¥2,172 million, while operating income declined 27.8% to ¥451 million yen.

Furthermore, total overseas sales excluding Japan came to ¥52,935 million, an increase of 9.4%, accounting for 45.4% of the Company's total net sales.

[Cash flow]

Net cash provided by operating activities in the 1st quarter amounted to ¥16,949 million, an increase of ¥4,822 million from the preceding year. Income before income taxes rose ¥1,237 million from the previous year to ¥19,401 million. Meanwhile, depreciation and amortization expenses came to ¥4,292 million which remained at almost the same level as the same period of the previous year, while trade receivables declined by ¥13,736 million and income taxes paid came to ¥21,629 million.

Cash flows from investing activities totaled ¥3,764 million, down ¥4,142 million from the previous year, of which ¥5,021 million was used for acquisition of tangible fixed assets. Meanwhile, net cash used in financing activities amounted to ¥4,705 million, a decrease of ¥856 million, due to the payment of dividends and other activities.

As a result of operating, investing and financing activities, cash and cash equivalents at the end of the period under review increased by ¥9,128 million from the end of the previous period, to ¥136,400 million.

[Products under development]

The additional indication of acute pulmonary embolism was acquired in May in Japan for

**3. FORECASTED CONSOLIDATED FINANCIAL RESULTS FOR THE FISCAL YEAR ENDING MARCH 31, 2004**

Period	Net Sales	Ordinary Income	Net Income	Earnings per Share (EPS)
April 1, 2003- September 30, 2003	¥243,000 mil.	¥40,500 mil.	¥24,000 mil.	¥82.25
April 1, 2003- March 31, 2004	¥500,000 mil.	¥80,000 mil.	¥48,000 mil.	¥164.27

**(REFERENCE DATA 2)**

**FORECASTED NON-CONSOLIDATED FINANCIAL RESULTS FOR THE FISCAL YEAR ENDING MARCH 31, 2004**

Period	Net Sales	Ordinary Income	Net Income
April 1, 2003- September 30, 2003	¥148,000 mil.	¥35,500 mil.	¥21,000 mil.
April 1, 2003- March 31, 2004	¥296,000 mil.	¥63,000 mil.	¥38,000 mil.

For the period ending March, 2004, no financial results forecast revisions have been made to the half-year or the full year period announced in May 2003. Although a difficult competitive environment continues both in Japan and overseas, the Company strives for further growth through expanding the sales of *Pariet* in Japan with the recent GERD maintenance indication approval, strengthening the sales force in the U.S., and improving managerial resource efficiency.

Period	Dividends per Share		
	Interim	Year End	Annual
April 1, 2003- September 30, 2003	¥18.00	—	—
April 1, 2003- March 31, 2004	—	¥18.00	¥36.00

Note: The forward-looking statements contained in this report are based on information available to the Company at the time they were issued, and actual results could differ materially from these statements due to changes in economic conditions, foreign exchange rates, conditions affecting the pharmaceutical industry including revisions of the pharmaceutical affairs system, and other factors.

EISAI CO., LTD.

1-1) CONSOLIDATED BALANCE SHEET (ASSETS)

	(%)	(%)	Increase (Decrease) (Millions of Yen)
<b>ASSETS</b>			
<b>Current assets:</b>			
Cash and bank account	101,263	114,010	

## EISAI CO., LTD.

## 1-2) CONSOLIDATED BALANCE SHEET

## (LIABILITIES, MINORITY INTERESTS AND SHAREHOLDERS' EQUITY)

Account Title	March 31, 2003		June 30, 2003		Increase (Decrease)
	(Millions of Yen)	(%)	(Millions of Yen)	(%)	(Millions of Yen)
<b>LIABILITIES</b>					
<b>Current liabilities:</b>					
Accounts payable-trade	16,134		14,912		
Short-term borrowings	35		226		
Current portion of straight bonds	100		100		
Accounts payable-other	41,145		39,716		
Accrued expenses	22,595		26,504		
Accrued income taxes	23,026		12,910		
Reserve for sales rebates	37,574		34,650		
Other reserves	796		978		
Other current liabilities	4,584		5,472		
<b>Total current liabilities</b>	145,992	24.7	135,472	22.8	(10,519)
<b>Long-term liabilities:</b>					
Deffered tax liabilities	344		485		
Liability for retirement benefits	45,417		49,049		
Retirement allowances for directors	1,764		1,762		
Consolidation account adjustment	178		163		
Other long-term liabilities	443		432		
<b>Total long-term liabilities</b>	48,148	8.1	51,892	8.7	3,744
<b>Total liabilities</b>	194,140	32.8	187,365	31.5	(6,775)
<b>Minority interests</b>	9,332	1.6	9,336	1.6	33
<b>Shareholders' equity:</b>					
Common stock	44,985	7.6	44,985	7.6	—
Capital surplus	55,222	9.3	55,222	9.3	—
Retained earnings	302,669	51.2	310,269	52.2	7,600
Net unrealized gain (loss) on available-for-sale securities	1,424	0.2	2,295	0.4	871
Foreign currency translation adjustment	(1,502)	(0.2)	(993)	(0.2)	509
Treasury stock	(14,551)	(2.5)	(14,556)	(2.4)	(4)
<b>Total shareholders' equity</b>	388,247	65.6	397,223	66.9	8,975
<b>Total</b>	591,721	100.0	593,955	100.0	2,233



## EISAI CO., LTD.

## 2. CONSOLIDATED STATEMENTS OF INCOME

The First Quarter for 2002 and 2003

Account Title	April 1, 2002 - June 30, 2002		April 1, 2003 - June 30, 2003		Increase (Decrease)		
	(Millions of Yen)	(%)	(Millions of Yen)	(%)	(Millions of Yen)		
<b>Net sales</b>		115,187	100.0		116,649	100.0	1,461
Cost of sales		27,884	24.2		22,843	19.6	(5,040)
Gross profit on sales		87,303	75.8		93,805	80.4	6,502
Provision of reserve for sales returns		95	0.1		117	0.1	21
<b>Gross profit</b>		87,208	75.7		93,688	80.3	6,480
<b>Selling and general administrative expenses</b>							
Research and development expenses	13,512			16,896			
Selling and general administrative expenses	54,673	68,186	59.2	57,713	74,609	64.0	6,423
<b>Operating income</b>		19,022	16.5		19,078	16.4	56
<b>Non-operating income</b>		1,196	1.0		773	0.7	(423)
<b>Non-operating expenses</b>		1,869	1.6		281	0.2	(1,588)
<b>Ordinary income</b>		18,348	15.9		19,571	16.8	1,222
<b>Extra-ordinary income</b>		29	0.0		472	0.4	443
<b>Extra-ordinary loss</b>		213	0.1		642	0.6	428
<b>Income before income taxes and minority interests</b>		18,164	15.8		19,401	16.6	1,237
<b>Income taxes-current</b>	10,550			11,514			
<b>Income taxes-deferred</b>	(3,563)	6,987	6.1	(4,478)	7,036	6.0	49
<b>Minority interests</b>		(2)	(0.0)		30	0.0	32
<b>Net income</b>		11,180	9.7		12,335	10.6	1,155

EISAI CO., LTD.

3. CONSOLIDATED STATEMENTS OF CASH FLOWS

The First Quarter for 2002 and 2003

April 1, 2002- June 30, 2002	April 1, 2003- June 30, 2003	Increase (Decrease)
(Millions of Yen)	(Millions of Yen)	(Millions of Yen)

## 4. SEGMENT INFORMATION

### 1. Industry Segment Information

(1) For the first quarter, ended June 30, 2002

( Millions of Yen )

	Pharma- ceuticals	Others	Total	Eliminations and Corporate	Consolidated
I. Sales					
(1) Sales to customers	¥108,106	¥7,081	¥115,187	-	¥115,187
(2) Intersegment sales	50	3,273	3,324	(¥3,324)	-
Total sales	108,157	10,354	118,512	(3,324)	115,187
Operating expenses	88,884	9,882	98,766	(2,600)	96,165
Operating income	¥19,273	(¥472)	¥19,745	(¥723)	¥19,022

(2) For the first quarter, ended June 30, 2003

( Millions of Yen )

Pharma-

, ,

(2) For the first quarter ended June 30, 2003

( Millions of Yen )

	Japan	North America	Europe	Asia and Others	Total	Eliminations and Corporate	Consolidated
I. Sales							
(1) Sales to customers	¥63,713	¥42,258	¥8,505	¥2,172	¥116,649	–	¥116,649
(2) Intersegment sales	17,568	4,146	685	16	22,416	(22,416)	–
Total sales	81,282	46,404	9,190	2,188	139,066	(22,416)	116,649
Operating expenses	61,181	45,109	8,643	1,737	116,672	(19,101)	97,570
Operating income	¥20,100	¥1,294	¥547	¥451	¥22,393	(¥3,314)	¥19,078

Notes:


(1) Segmentation by country or region is based on geographical proximity.

(2) Major areas and countries included in each category:

-North America: The United States and Canada

-Europe: The United Kingdom, Germany, France, etc.

-Asia: China, India, France, etc.



2003

## Reference Data

First Quarter Ended June 30, 2003

---

**Eisai Co., Ltd.**

**July 30, 2003**

**For Inquiry: Public Relations Department**

**TEL 81-3-3817-5120 FAX 81-3-3811-3077**

**<http://www.eisai.co.jp/eir/>**

## Contents

	Pages
I. Consolidated Financial Highlights .....	1
II. Consolidated Statements of Income .....	2
III. Consolidated Balance Sheet .....	8
IV. Consolidated Statements of Cash Flows .....	10
V. Non-consolidated Financial Highlights .....	11
VI. Changes in Quarterly Results .....	14
VII. Major R&D Pipeline Candidates .....	17
VIII. Major News Releases .....	19

\*Unless otherwise specified, all figures have been rounded to their nearest specified unit.

\*Currency exchange rates utilized in the reference data are noted in the table below.

### Currency Exchange Rates

	US	EU	UK
	(¥/US\$)	(¥/EURO)	(¥/£)
(Apr. - Jun. 2002) First Quarter Average Rate	127.04	116.57	185.52
(Mar. 31, 2003) Fiscal Year End Rate	120.20	129.83	189.45
(Apr. - Jun. 30, 2003) First Quarter Average Rate	118.50	134.66	191.82
(Jun. 30, 2003) First Quarter End Rate	119.80	136.92	198.11
Fiscal Year Ending March 31, 2004 Forecast Rate	115.00	120.00	190.00

\*Quarterly financial results for the previous fiscal year ended on March 31, 2003 stated in this material are for reference use only because the company has initiated disclosure of its quarterly results from the current fiscal year.

\*The Company's performance and financial results could differ materially from those reflected in these forward-looking statements due to general, financial, economic, and political conditions affecting the pharmaceutical industry.

# I. Consolidated Financial Highlights

## 1. Statement of Income Data

(billions of yen)

Years Ended/Ending March 31	2003	2004	Change %	2003	2004 (e)
Net Sales	115.2	<b>116.6</b>	101.3	466.6	500.0
Cost of Sales	28.0	<b>23.0</b>	82.1	102.6	100.0
Research and Development Expenses	13.5	<b>16.9</b>	125.0	59.7	67.0
Selling, General and Administrative Expenses	54.7	<b>57.7</b>	105.6	228.4	253.0
Operating Income	19.0	<b>19.1</b>	100.3	75.9	80.0
Ordinary Income	18.3	<b>19.6</b>	106.7	76.1	80.0
Net Income	11.2	<b>12.3</b>	110.3	41.0	48.0
Earnings per Share (yen)	38.3	<b>42.3</b>	110.3	141.2	164.3

\*\*Cost of Sales" includes "Reversal of reserve for sales returns".

## 2. Balance Sheet Data

(billions of yen)

	31-Mar	30-Jun	Inc./ Dec.
Total Assets	591.7	<b>594.0</b>	2.2
Shareholders' Equity	388.2	<b>397.2</b>	9.0

## 3. Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	2003	2004	Inc./ Dec.	2003	2004 (e)
Capital Expenditures	3.2	<b>5.2</b>	1.9	21.9	24.5
Property, plant and equipment	2.8	<b>4.5</b>	1.7	17.4	20.0
Intangible Assets	0.4	<b>0.7</b>	0.2	4.5	4.5
Depreciation/Amortization	4.1	<b>4.3</b>	0.2	18.0	18.0

\* Depreciation/amortization includes "Property, plant and equipment" and "Intangible assets".

## 4. Cash Flow Data

(billions of yen)

Years Ended/Ending March 31	2003	2004	Inc./ Dec.	2003	2004 (e)
Net cash provided by operating activities	12.1	<b>16.9</b>	4.8	57.6	-
Net cash used in investing activities	(7.9)	<b>(3.8)</b>	4.1	(27.7)	-
Net cash used in financing activities	(5.4)	<b>(4.5)</b>	0.9	(19.8)	-
Cash and cash equivalents at end of period	115.8	<b>136.4</b>		127.3	-

## II. Consolidated Statements of Income

### 1. Consolidated Statement of Income & Explanation (billions of yen)

Years Ended/Ending March 31	2003 %	Sales	2004 %	Sales	Chg. %	Inc./ Dec.
<b>Net sales</b>	115.2	100.0	<b>116.6</b>	100.0	101.3	1.5
Cost of sales	27.9	24.2	<b>22.8</b>	19.6	81.9	(5.0)
Reversal of reserve for sales returns	0.1	0.1	<b>0.1</b>	0.1	122.7	0.0
<b>Gross profit</b>	87.2	75.7	<b>93.7</b>	80.3	107.4	6.5
Research and development expenses	13.5	11.7	<b>16.9</b>	14.5	125.0	3.4
Selling, general and administrative expenses	54.7	47.5	<b>57.7</b>	49.4	105.6	3.0
<b>Operating income</b>	19.0	16.5	<b>19.1</b>	16.4	100.3	0.1
Non-operating income	1.2	1.0	<b>0.8</b>	0.7	64.6	(0.4)
Non-operating expenses	1.9					

<Explanation>



## 2. Financial Results by Industry Segment

### 2-1. Consolidated Net Sales by Industry Segment

(billions of yen)

Years Ended/Ending March 31	First Quarter			2003
	2003	2004	Change %	
Net sales to customers	115.2	<b>116.6</b>	101.3	466.6
Pharmaceuticals	108.1	<b>111.2</b>	102.9	441.7
(In-house developed products %)	(85.2%)	<b>(89.3%)</b>	-	(89.3%)
Japan	60.2	<b>59.1</b>	98.0	228.0
North America	38.9	<b>41.7</b>	107.3	178.4
Europe	6.6	<b>8.3</b>	124.5	26.1
Asia and others	2.3	<b>2.2</b>	93.3	9.1
Others	7.1	<b>5.4</b>	76.6	24.9
Japan	6.6	<b>4.7</b>	71.0	22.6
Overseas	0.5	<b>0.8</b>	148.7	2.3

\* Sales results by industry segment have been reclassified in accordance with geographical segmentation.

\* Major areas and countries included in each category:

1. North America: The U.S. and Canada
2. Europe: The United Kingdom, Germany, France, etc.
3. Asia and Others: East Asia, South-East Asia, and South-Central America, etc.

### 2-2. Consolidated Operating Income by Industry Segment

(billions of yen)

Years Ended/Ending March 31	First Quarter			2003
	2003	2004	Change %	
Operating income/loss	19.0	<b>19.1</b>	100.3	75.9
Pharmaceutical	19.3	<b>19.4</b>	100.6	77.7
Others	0.5	<b>0.4</b>	78.1	0.7
Elimination and Corporate	(0.7)	<b>(0.7)</b>		(2.5)

### 3. Financial Results by Geographical Area

#### 3-1. Consolidated Net Sales by Geographical Segment

(billions of yen)

Years Ended/Ending March 31	First Quarter			
	2003	2004	Change %	2003
Net sales to customers	115.2	<b>116.6</b>	101.3	466.6
Japan	66.8	<b>63.7</b>	95.4	250.6
North America	39.1	<b>42.3</b>	108.0	179.5
Europe	6.9	<b>8.5</b>	122.6	27.3
Asia and others	2.3	<b>2.2</b>	93.3	9.1
Overseas sales	48.4	<b>52.9</b>	109.4	216.0
Overseas sales (%)	42.0%	<b>45.4%</b>	-	46.3%

#### 3-2. Consolidated Operating Income by Geographical Segment

(billions of yen)

Years Ended/Ending March 31	First Quarter			
	2003	2004	Change %	2003
Operating income/loss	19.0	<b>19.1</b>	100.3	75.9
Japan	21.0	<b>20.1</b>	95.9	70.2
North America	0.5	<b>1.3</b>	257.5	5.7
Europe	0.6	<b>0.5</b>	97.3	2.4
Asia and others	0.6	<b>0.5</b>	72.2	1.7
Eliminations and corporate	(3.6)	<b>(3.3)</b>		(4.1)

### 4. Overseas Sales

(billions of yen)

Years Ended/Ending March 31	First Quarter			
	2003	2004	Change %	2003
Net sales	115.2	<b>116.6</b>	101.3	466.6
North America	39.7	<b>44.5</b>	112.1	185.9
Europe	10.3	<b>10.3</b>	100.5	36.0
Asia and others	3.1	<b>2.9</b>	96.3	11.6
Overseas sales	53.0	<b>57.7</b>	108.9	233.5
Overseas sales (%)	46.0%	<b>49.5%</b>	-	50.0%

\* Sales results by industry segment have been reclassified in accordance with geographical segmentation.

\* Major areas and countries included in each category:

1. North America: The U.S. and Canada
2. Europe: The United Kingdom, Germany, France, etc.
3. Asia and Others: East Asia, South-East Asia, and South-Central America, etc.

## 5. Global Product Sales

### 5-1. ARICEPT Sales by Area

Years Ended/Ending March 31		2003	<b>2004</b>	Change %	2003
Area					
Japan	¥ Billions	5.4	<b>7.0</b>	130.2	21.9
U.S.	¥ Billions	14.8	<b>19.1</b>	129.5	74.5
	US \$ Millions	116	<b>162</b>	133.8	611
U.K.	¥ Billions	0.5	<b>0.3</b>	59.5	0.9
	UK £ Millions	3	<b>1</b>	57.5	5
Germany	¥ Billions	1.5	<b>2.1</b>	137.7	4.4
	Euro Millions	13	<b>15</b>	119.2	37
France	¥ Billions	2.6	<b>3.4</b>	132.0	11.3
	Euro Millions	22			

## <Reference> [Non-consolidated]

### Eisai Inc. (U.S.A.) / Pharmaceutical Sales, Production

Years Ended/Ending March 31		First Quarter			2003
		2003	2004	Change %	
Net sales	¥ Billions	40.2	<b>42.4</b>	105.6	181.7
	US \$ Millions	316	<b>358</b>	113.2	1,490
Operating income	¥ Billions	0.6	<b>1.0</b>	155.1	6.3
	US \$ Millions	5	<b>8</b>	166.2	52
Net income	¥ Billions	0.5	<b>0.7</b>	130.0	3.9
	US \$ Millions	4	<b>5</b>	139.3	32
Operating income before Royalty deduction	¥ Billions	4.8	<b>6.2</b>	129.3	27.0
	US \$ Millions	38	<b>53</b>	138.6	222

### Eisai China Inc. (China) / Pharmaceutical Sales, Production

Years Ended/Ending March 31		First Quarter			2003
		2003	2004	Change %	
Net sales	¥ Billions	0.8	<b>0.8</b>	91.3	3.3
	Chinese RMB Millions	51	<b>52</b>	101.7	221
Operating income	¥ Billions	0.3	<b>0.2</b>	68.6	0.9
	Chinese RMB Millions	20	<b>15</b>	76.5	61
Net income	¥ Billions	0.3	<b>0.2</b>	66.2	0.8
	Chinese RMB Millions	20	<b>15</b>	73.7	56

\*The fiscal year of Eisai China Inc. ends on December 31. Average rate of Japanese yen to Chinese Yuan was 15.14 yen from January 1 to December 31, 2002, 14.37 yen from January 1, 2003 to March 31, 2003 and 16.01 yen from January 1, 2002 to March 2002, respectively.

### Eisai Korea Inc. (Korea) / Pharmaceutical Sales

Years Ended/Ending March 31		First Quarter			2003
		2003	2004	Change %	
Net sales	¥ Billions	0.5	<b>0.5</b>	103.1	2.0
	Korean Won Billions	5	<b>5</b>	105.1	20
Operating income	¥ Billions	0.1	<b>0.1</b>	118.5	0.2
	Korean Won Billions	1	<b>1</b>	120.9	2
Net income	¥ Billions	0.0	<b>0.0</b>	124.1	0.2
	Korean Won Billions	0	<b>0</b>	126.6	2

\*FY2002 average rate was 0.100 yen to the Korean Won.

\*Average rate of Japanese yen to Korean won was 0.099 yen from April 1 to June 30 2003 and 0.101 yen from April 1 to June 30, 2002, respectively.

## 6. Selling, General and Administrative Expenses (Including R&D expenses)

### 6-1. Research and Development Expenses (R&D expenses)

(billions of yen)

Years Ended/Ending March 31	First Quarter		2003	2004 (e)
	2003	2004		
Net sales	115.2	<b>116.6</b>	466.6	500.0
Research and development expenses	13.5	<b>16.9</b>	59.7	67.0
Percentage of sales (%)	11.7%	<b>14.5%</b>	12.8%	13.4%

### 6-2. Selling, General and Administrative Expenses (SG&A expenses)

(billions of yen)

Years Ended/Ending March 31	First Quarter		2003	2004 (e)
	2003	2004		
Net sales	115.2	<b>116.6</b>	466.6	500.0
Selling, general and administrative expenses	54.7	<b>57.7</b>	228.4	253.0
Personnel expenses	15.1	<b>15.5</b>	55.7	-
Marketing expenses	33.1	<b>35.5</b>	147.4	-
Administrative expenses and others	6.4	<b>6.8</b>	25.4	-
Percentage of sales (%)	47.5%	<b>49.4%</b>	48.9%	50.6%

### 6-3. Selling General and Administrative Expenses (Including R&D Expenses)

(billions of yen)

Years Ended/Ending March 31	First Quarter		2003	2004 (e)
	2003	2004		
Net sales	115.2	<b>116.6</b>	466.6	500.0
Selling, general and administrative expenses (including R&D expenses)	68.2	<b>74.6</b>	288.1	320.0
Percentage of sales (%)	59.2%	<b>64.0%</b>	61.8%	64.0%

# III. Consolidated Balance Sheet

## 1. Consolidated Balance Sheet & Explanation

<Assets>

(billions of yen)

--	--

## <Liabilities and Shareholders' Equity>

(billions of yen)

	2003		%	Chg. %	Inc./ Dec.	<Explanation>
	31-Mar	30-Jun				
<b>Current liabilities:</b>						
Accounts payable-trade	16.1	<b>14.9</b>			(1.2)	<b>Accrued income taxes</b> <Decrease Factor(s)> Decrease due to settlement of income tax payable
Short-term borrowings	0.0	<b>0.2</b>			0.2	
Current portion of straight bonds	0.1	<b>0.1</b>			-	
Accounts payable-other	41.1	<b>39.7</b>			(1.4)	
Accrued expenses	22.6	<b>26.5</b>			3.9	
Accrued income taxes	23.0	<b>12.9</b>			(10.1)	
Reserve for sales rebates	37.6	<b>34.7</b>			(2.9)	
Other reserves	0.8	<b>1.0</b>			0.2	
Other current liabilities	4.6	<b>5.5</b>			0.9	
<b>Total current liabilities</b>	<b>146.0</b>	<b>135.5</b>	22.8	92.8	(10.5)	
<b>Long-term liabilities:</b>						
Deferred tax liabilities	0.3	<b>0.5</b>			0.1	<b>Liabilities for retirement benefits</b> Amortization of actuarial loss
Liabilities for retirement benefits	45.4	<b>49.0</b>			3.6	
Allowance for retirement of Directors	1.8	<b>1.8</b>			(0.0)	
Consolidated adjustment account	0.2	<b>0.2</b>			(0.0)	
Other long-term liabilities	0.4	<b>0.4</b>			(0.0)	
<b>Total long-term liabilities</b>	<b>48.1</b>	<b>51.9</b>	8.7	107.8	3.7	
<b>Total liabilities</b>	<b>194.1</b>	<b>187.4</b>	31.5	96.5	(6.8)	
<b>Minority Interests</b>	<b>9.3</b>	<b>9.4</b>	1.6	100.4	0.0	
<b>Shareholders' equity:</b>						
Common stock	45.0	<b>45.0</b>	7.6		-	
Capital surplus	55.2	<b>55.2</b>	9.3		-	
Retained earnings	302.7	<b>310.3</b>	52.2		7.6	
Net unrealized gains on available-for-sale securities	1.4	<b>2.3</b>	0.4		0.9	
Foreign currency translation adjustments	(1.5)	<b>(1.0)</b>	(0.2)		0.5	
Treasury stock	(14.6)	<b>(14.6)</b>	(2.4)		(0.0)	
<b>Total shareholders' equity</b>	<b>388.2</b>	<b>397.2</b>	66.9	102.3	9.0	
<b>Total liabilities, minority interests and shareholders' equity</b>	<b>591.7</b>	<b>594.0</b>	100.0	100.4	2.2	

# IV. Consolidated Statements of Cash Flows

(billions of yen)

Years Ended/Ending March 31





## V. Non-Consolidated Financial Highlights

### 1. Statements of Income Data

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Net Sales	76.8	<b>76.5</b>	99.5	289.6	296.0
Cost of Sales	22.9	<b>20.8</b>	90.6	85.6	80.0
Research and Development Expenses	12.9	<b>16.0</b>	124.6	57.6	64.0
Selling, General and Administrative Expenses	20.8	<b>20.6</b>	98.9	81.1	89.0
Operating Income	20.3	<b>19.1</b>	94.3	65.3	63.0
Ordinary Income	19.1	<b>19.6</b>	102.8	64.8	63.0
Net Income	11.4	<b>12.3</b>	107.9	34.2	38.0
Earnings per Share (yen)	39.0	<b>42.0</b>	107.8	117.6	-

### 2. Net Sales by Business Segment

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Net Sales (billions of yen)	76.8	<b>76.5</b>	99.5	289.6	296.0
Pharmaceuticals	67.1	<b>67.2</b>	100.1	250.2	258.5
Prescription Pharmaceuticals(Including Drug Substance/Bulk Tablets)	62.0	<b>62.8</b>	101.3	229.4	238.0
(Ratio of in-house developed products to Prescription Pharmaceuticals) (%)	(77.7%)	<b>(79.0%)</b>	-	(78.0%)	-
Consumer Health Care Products	5.1	<b>4.3</b>	85.4	20.8	20.5
Food Additives/Chemicals, Machinery, etc.	3.9	<b>2.2</b>	56.7	11.9	8.0
Industrial Property Rights, etc. Income	5.8	<b>7.1</b>	121.7	27.5	29.5

\*Animal Health business was transferred to other company in February 2003.

### 3. Exports by Geographical Area

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Net Sales	76.8	<b>76.5</b>	99.5	289.6	296.0
Export	19.5	<b>22.3</b>	114.4	76.5	72.0
North America	13.9	<b>16.5</b>	118.1	54.9	-
Europe	4.5	<b>4.5</b>	101.1	17.5	-
Asia and Others	1.1	<b>1.3</b>	121.2	4.1	-
Ratio of Exports to Sales(%)	25.4%	<b>29.2%</b>	-	26.4%	24.3%

\* Major areas and countries included in each category:

1. North America: The U.S. and Canada
2. Europe: The United Kingdom, Germany, France, etc.
3. Asia and Others: East Asia, South-East Asia, and South-Central America, etc.

## 4. Prescription Pharmaceuticals

(billions of yen)

Years Ended/Ending March 31		2003	2004	Change %	2003	2004
Product	Description					(e)
	Peripheral neuropathy treatment					
METHYCOBAL		8.4	<b>8.3</b>	99.8	31.1	32.0
	Alzheimer's disease treatment					
ARICEPT		5.4	<b>7.0</b>	130.2	21.9	30.0
	Gastritis/gastric ulcer medication					
SELBEX		7.2	<b>6.7</b>	93.2	26.8	26.0
	Osteoporosis treatment					
GLAKAY		3.2	<b>2.8</b>	86.9	11.4	11.0
	Non-ionic contrast medium					
IOMERON		2.5	<b>2.6</b>	103.0	9.5	9.0
	Muscle relaxant					
MYONAL		2.4	<b>2.3</b>	94.9	8.8	9.0
	Proton pump inhibitor					
PARIET		1.6	<b>1.7</b>	109.6	5.8	18.0
	Long-acting isosorbide dinitrate					
NITOROL-R		1.8	<b>1.4</b>	82.0	6.1	6.0
	Endoscopic examination/hypoglycemia treatment					
GLUCAGON G NOVO		1.2	<b>1.2</b>	99.0	4.4	4.5
	Anti-allergy agent					
AZEPTIN		1.3	<b>1.0</b>	75.6	4.8	5.0
	Long-acting macrolide antibiotic					
RULID		0.9	<b>0.8</b>	89.4	3.5	3.0
	Long-acting ACE inhibitor					
INHIBACE		0.9	<b>0.7</b>	79.1	3.1	3.0
Prescription Pharmaceuticals Total		49.6	<b>48.9</b>	98.5	185.7	197.0

## 5. ACIPHEX/PARIET, ARICEPT Drug Substance / Bulk Tablets Sales

(billions of yen)

Years Ended/Ending March 31		2003	2004	Change %	2003	2004
						(e)
	ACIPHEX/PARIET bulk tablets/drug substance (export)	8.1	<b>9.4</b>	116.5	28.9	27.0
	ARICEPT drug substance (export)	4.4	<b>4.6</b>	104.5	14.6	15.4

## 7. Selling, General and Administrative Expenses (including R&D expenses)

### 7-1. Research and Development Expenses (R&D expenses)

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Net sales	76.8	<b>76.5</b>	99.5	289.6	296.0
Research and development expenses	12.9	<b>16.0</b>	124.6	57.6	64.0
Percentage of sales (%)	16.7%	<b>21.0%</b>	-	19.9%	21.6%

### 7-2. Selling, General and Administrative Expenses (SG&A expenses)

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Net sales	76.8	<b>76.5</b>	99.5	289.6	296.0
Selling, general and administrative expenses	20.8	<b>20.6</b>	98.9	81.1	89.0
Personnel expenses	9.6	<b>9.9</b>	103.1	37.6	-
Marketing expenses	6.9	<b>6.6</b>	95.0	26.8	-
Administrative expenses and others	4.3	<b>4.1</b>	96.0	16.7	-
Percentage of sales (%)	27.1%	<b>26.9%</b>	-	28.0%	30.1%

### 7-3. Selling, General and Administrative Expenses (including R&D expenses)

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Net sales	76.8	<b>76.5</b>	99.5	289.6	296.0
Selling, general and administrative expenses (including R&D)	33.7	<b>36.6</b>	108.7	138.7	153.0
Percentage of sales (%)	43.8%	<b>47.9%</b>	-	47.9%	51.7%

## 8. Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	First Quarter				
	2003	2004	Change %	2003	2004 (e)
Capital expenditures	1.8	<b>3.5</b>	189.9	15.9	160.0
Property, plant and equipment	1.4	<b>2.9</b>	202.9	11.6	12.5
Intangible assets	0.4	<b>0.6</b>	142.8	4.4	3.5
Depreciation/Amortization	3.0	<b>3.1</b>	104.0	13.0	13.0

Note: Depreciation/amortization includes "Property, plant and equipment" as well as "Intangible assets".

## VI. Changes in Quarterly Results

### 1. Consolidated Statement of Income Data

(billions of yen)

Years Ended/Ending March 31	2003				2004
		Third Quarter	Fourth Quarter	First Quarter	
Net sales	115.2	119.2	117.7	114.4	<b>116.6</b>
Cost of sales	28.0	24.9	26.5	23.3	<b>23.0</b>
Research and development expenses	13.5	14.4	14.8	17.1	<b>16.9</b>
Selling, general and administrative expenses	54.7	58.6	54.9	60.2	<b>57.7</b>
Operating income	19.0	21.4	21.6	13.8	<b>19.1</b>
Ordinary income	18.3	21.7	21.7	14.3	<b>19.6</b>
Net income	11.2	11.1	12.9	5.8	<b>12.3</b>
Earnings per share (yen)	38.3	38.1	44.6	20.1	<b>42.3</b>

\*"Cost of Sales" includes "Reversal of reserve for sales returns".

### 2. Consolidated Balance Sheet Data

(billions of yen)

Years Ended/Ending March 31	2002				2003
	First Quarter	30-Jun	30-Sep	31-Dec	31-Mar
Total assets	556.6	558.3	591.0	591.7	<b>594.0</b>
Shareholders' equity	369.8	376.9	388.2	388.2	<b>397.2</b>

### 3. Consolidated Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	2003				2004
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
Capital expenditures	3.2	6.0	4.4	8.3	<b>5.2</b>
Property, plant and equipment	2.8	4.6	3.6	6.4	<b>4.5</b>
Intangible assets	0.4	1.3	0.8	1.9	<b>0.7</b>
Depreciation/Amortization	4.1	4.4	4.5	4.9	<b>4.3</b>

### 4. Consolidated Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	2003				2004
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
Net cash provided by operating activities	12.1	7.4	6.2	31.9	<b>16.9</b>
Net cash used in investing activities	(7.9)	(10.1)	(2.9)	(6.8)	<b>(3.8)</b>
Net cash used in financing activities	(5.4)	(9.3)	(4.3)	(0.9)	<b>(4.5)</b>
Effect of exchange rate changes on cash and cash equivalents	115.8	104.6	103.2	127.3	<b>136.4</b>
Free cash flow	5.1	0.2	1.8	24.0	<b>12.1</b>

Note: Free Cash Flow = "Net cash provided by operating activities" + "Capital expenditures" + "Other revenue/payment for continuous activities"

## 5. Consolidated *ARICEPT* Sales by Area

(billions of yen)

Years Ended/Ending March 31		2003				2004
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
Japan	¥ Billions	5.4	5.5	6.1	4.8	<b>7.0</b>
North America	¥ Billions	14.8	18.7	21.2	19.9	<b>19.1</b>
	US \$ Millions	116	155	173	166	<b>162</b>
EU total	¥ Billions	4.6	4.0	4.1	3.9	<b>5.8</b>
Asia and others	¥ Billions	0.7	0.6	0.4	0.6	<b>0.6</b>
Total	¥ Billions	25.4	28.8	31.9	29.2	<b>32.5</b>

## 6. Consolidated *ACIPHEX/PARIET* Sales by Area

(billions of yen)

Years Ended/Ending March 31		2003				2004
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
Japan	¥ Billions	1.6	1.4	1.6	1.2	<b>1.7</b>
North America	¥ Billions	24.1	26.7	20.3	32.7	<b>22.6</b>
	US \$ Millions	190	223	166	272	<b>191</b>
EU total	¥ Billions	1.5	1.2	2.2	1.6	<b>1.6</b>
Asia and others	¥ Billions	0.3	0.3	0.4	0.3	<b>0.3</b>
Total	¥ Billions	27.6	29.7	24.4	35.8	<b>26.3</b>

## 7. Non-Consolidated *ACIPHEX/PARIET, ARICEPT* Drug Substance / Bulk Tablets Sales

(billions of yen)

Years Ended/Ending March 31		2003				2004
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
ACIPHEX/PARIET bulk tablets/drug substance (export)		8.1	7.9	7.6	5.3	<b>9.4</b>
ARICEPT drug substance (export)		4.4	3.1	3.6	3.7	<b>4.6</b>
Bulk substance / Tablets total		12.5	11.1	11.1	9.1	<b>14.0</b>

## 7. Non-Consolidated Statement of Income Data

(billions of yen)

Years Ended/Ending March 31	2003				2004
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
Net sales	76.8	73.4	77.7	61.7	<b>76.5</b>
Operating income	20.3	17.2	20.6	7.2	<b>19.1</b>
Ordinary income	19.1	17.6	20.6	7.6	<b>19.6</b>
Net income	11.4	8.4	12.4	2.1	<b>12.3</b>
Number of treasury stock (thousands of shares)	4,762	7,771	7,822	4,776	<b>4,778</b>

\*Stock numbers less than one thousand were omitted.

## 8. Non-Consolidated Prescription Pharmaceuticals

(billions of yen)

Years Ended/Ending March 31	2003				2004
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
METHYCOBAL	8.4	8.1	8.1	6.5	<b>8.3</b>
ARICEPT	5.4	5.5	6.1	4.8	<b>7.0</b>
SELBEX	7.2	6.7	7.2	5.7	<b>6.7</b>
GLAKAY	3.2	2.9	3.0	2.3	<b>2.8</b>
IOMERON	2.5	2.5	2.6	1.9	<b>2.6</b>
MYONAL	2.4	2.3	2.3	1.8	<b>2.3</b>
PARIET	1.6	1.5	1.6	1.2	<b>1.7</b>
NITOROL-R	1.8	1.5	1.6	1.2	<b>1.4</b>
GLUCAGON G NOVO	1.2	1.1	1.2	0.8	<b>1.2</b>
AZEPTIN	1.3	0.9	1.0	1.6	<b>1.0</b>
RULID	0.9	0.7	1.0	0.8	<b>0.8</b>
INHIBACE	0.9	0.8	0.8	0.6	<b>0.7</b>
Prescription Pharmaceuticals Total	49.6	46.4	49.4	40.3	<b>48.9</b>

## 9. Non-Consolidated Consumer Health Care Products

(billions of yen)

Years Ended/Ending March 31	2003				2004
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter
CHOCOLA BB Group	2.4	2.6	2.3	1.8	<b>2.5</b>
Vitamin-E Group	0.6	1.0	0.9	0.6	<b>0.6</b>
SACLON Group	0.6	0.7	0.8	0.5	<b>0.5</b>
NABOLIN Group	0.5	0.2	0.3	0.3	<b>0.2</b>
Consumer Health Care Total	5.1	5.7	5.7	4.3	<b>4.3</b>

## VII. Major R&D Pipeline Candidates

### Changes from Previous Disclosure

1. *Pariet* was approved for maintenance therapy for Reflux Esophagitis in Japan.
2. *CLEACTOR* was submitted for sNDA for the treatment of pulmonary embolism in Japan.
3. A rapid disintegration tablet form of *ARICEPT* was filed for approval in Japan.
4. Indication of vascular dementia (VaD) of *ARICEPT* was not approved by FDA in the US.

### 1. International Development

#### 1-1. Filed for Approval

(Product) Name (Research Code)	Area	Date	Description	Form.	Origin
ARICEPT	U.S.	Sep-02	Vascular Dementia	Tab.	In-house
E2020 (Additional indication)	E.U.	Oct-02	Currently used for the treatment of mild to moderate dementia of the Alzheimer's type. Non-approvable letter was received from FDA for vascular dementia (VaD) indication on July 3, 2003. Discussion with FDA regarding indication will continue.		

#### 1-2. Phase III

(Product) Name (Research Code)	Area	Expected Application	Description	Form.	Origin
ARICEPT E2020 (Additional indication)	U.S.	2005	Severe Dementia due to Alzheimer's disease  Currently used for the treatment of mild to moderate dementia of the Alzheimer's type. E2020 is now in phase III trials for the treatment of severe dementia due to Alzheimer's disease.	Tab.	In-house
ARICEPT E2020 (Additional indication)	E.U.	2005	Dementia associated with Parkinson's disease  Currently used for the treatment of mild to moderate dementia of the Alzheimer's type. E2020 is now in phase III trials for the treatment of dementia associated with Parkinson's disease.	Tab.	In-house

#### 1-3. Phase II

(Product) Name (Research Code)	Area	Description	Form.	Origin
E5564	U.S.	Septic Shock/Endotoxin Antagonist  A synthetic endotoxin antagonist effective against endotoxin from various types of gram negative bacteria. Under development for the treatment of sepsis.	Inj.	In-house
E5564	U.S.	Prevention of endotoxin-related complications after coronary artery bypass graft surgery  A synthetic endotoxin antagonist effective against endotoxin from various types of gram negative bacteria. Now in phase II development for the prevention of endotoxin-related complications after coronary artery bypass graft surgery.	Inj.	In-house
E7070	U.S. E.U.	Anti-cancer/Cell Cycle G1 Phase Arresting Agent  The compound induces apoptosis by inhibiting cell cycle progression in the G1 phase. Under development as an anti-cancer agent with a novel mechanism of action.	Inj.	In-house
ARICEPT E2020 (Additional indication)	U.S.	Migraine Prophylaxis  Currently used for the treatment of mild to moderate dementia of the Alzheimer's type. E2020 is now in phase II trials for the prophylaxis of migraine headaches.	Tab.	In-house
E2007	E.U.	Multiple Sclerosis, Epilepsy and Parkinson's disease / AMPA receptor antagonist  Selectively antagonizes the AMPA-type glutamate receptor and inhibits neuronal cell death. Under development as a treatment for multiple sclerosis, epilepsy and Parkinson's disease.	Tab.	In-house

## 2. Development in Japan

### 2-1. Approved

(Product) Name (Research Code)	Description	Date	Form.	Origin
PARIET	Maintenance Therapy for Gastroesophageal Reflux Disease(GERD)	Jul-03	Tab.	In-house
E3810 (Additional indication)	Already used for the treatment of peptic ulcers. Received an approval letter for a maintenance therapy for GERD.			

### 2-2. Filed for Approval

(Product) Name (Research Code)	Description	Application	Form.	Origin
MYONAL	Muscle Relaxant	Mar-97	Transdermal	In-house
E2000 (Additional form)	Absorption via a transdermal patch form has been shown to relieve central nervous skeletal muscle spasticity and to mitigate muscle stiffness and pain from poor circulation and is expected to improve various symptoms of muscle tension.			
ARICEPT	Rapid Disintegration Tablet	Mar-03	Rapid	In-house
E2020 (Additional form)	Already been used in tablet and fine granule forms. Filed for rapid disintegration tablet form.		Disintegration Tab.	
CLEACTOR	Treatment of Pulmonary Embolism	2003	Inj.	In-house
E6010 (Additional indication)	A novel second generation t-PA with a structure modified utilizing recombinant DNA techniques. Designated as an orphan drug, E6010 is expected to be the first t-PA indicated for the treatment of pulmonary embolism in Japan.			

### 2-3. Phase III

(Product) Name (Research Code)	Description	Expected Application	Form.	Origin
T-614	Anti-rheumatic Agent Inhibits lymphocyte proliferation and immunoglobulin production by suppressing the production of inflammatory cytokines. Expected to improve chronic rheumatoid arthritis.	2003	Tab.	Toyama Chemical
PARIET	Eradication of <i>H. Pylori</i> in combination with antibiotics	2005	Tab.	In-house
E3810 (Additional indication)	Currently used for the treatment of peptic ulcers in Japan. E3810 is now in phase III trials for the eradication of <i>H. Pylori</i> in combination with antibiotics.			

### 2-4. Phase II

(Product) Name (Research Code)	Description	Form.	Origin
E3620	Gastroprokinetic agent/5-HT7ipin		



## VIII. Major News Releases

Date	Description
July 30, 2003	Marketing alliance agreement for MAXALT, a migraine treatment agent is partially amended
July 30, 2003	Independent company will be established for chemicals and food additives business
July 18, 2003	PARIET 10 mg received approval for maintenance therapy for Gastroesophageal Reflux Disease(GERD)
July 4, 2003	FDA did not approve the indication of vascular dementia for ARICEPT
July 1, 2003	Notice concerning stock options including the amount to be paid for the exercise of stock options was announced
June 24, 2003	Notice of allotment of stock options was announced
June 23, 2003	Activated Vitamin B <sub>2</sub> tablet, CHOCOLA BB PLUS was launched in Japan
May 26, 2003	

July 30, 2003  
Eisai Co., Ltd.

**Consolidated Performance Report  
for the First Quarter ended March 31, 2003**

Eisai Co., Ltd. achieved steady performance during the first quarter with consolidated

5. Selling, general and administrative expenses increased 5.6% because of the sales force expansion in the U.S. and increased global sales growth.
6. Because of the reasons described above, operating income slightly increased, and

### 3. Enhancement of profitability in the U.S.

The profitability of Eisai Inc, our U.S. sales subsidiary, improved. Operating income before royalty deduction grew 39% (YOY), and this ratio to sales increased by 2.7%, from 12.0 in the previous year to 14.7%.

### 4. Expansion of the sales force in the U.S.

Eisai Inc. increased its sales force to a total of 400 by adding 150 sales representatives. They started promotion in June after completing a training period. Their contribution to sales growth will occur in or after the second quarter. SOV (share of voice) of *Aciphex*, including efforts of our alliance partner, increased in a six month period by over 40% in comparison to the previous six month period. For *Aricept*, in addition to increasing sales representatives, a DTC (Direct to Consumer) campaign will be initiated in the future to improve public awareness of dementia of the Alzheimer's type, and the Company aims to expand prescriptions of the product.

### 5. Partnership with Teva Pharmaceutical Industries Ltd.

Eisai concluded an agreement for the co-development of *rasagiline* for Alzheimer's disease, and co-promotion for Parkinson's disease in the U.S. with Teva Pharmaceutical Industries Ltd. Rasagiline is expected to be submitted for regulatory approval for Parkinson's disease in the U.S. during the second half of 2003. Once approved, Eisai and Teva will co-promote the product.

The two companies will co-develop rasagiline for Alzheimer's disease, utilizing its MAO-B inhibitor action, which is different from that of Aricept. With this joint research, Eisai aims to contribute to improving the lives of patients, and expand the coverage of Alzheimer's disease treatment agents.

[The Significant Events after Closing Date of the First Quarter Period]

### 6. Supplementary approval for dosage and administration of *Pariet* in Japan

*Pariet* received approval for maintenance therapy for gastroesophageal reflux disease on July 17, 2003 in Japan. With this approval, *Pariet* may be administered for more than eight weeks. The daily dosage of *Pariet* for both treatment and maintenance is the

same dosage, and treated patients can shift to maintenance therapy without changing the dose.

Eisai aims to achieve a sales target of 1.8 billion yen for 2003 in Japan as originally projected, with this supplementary approval.

#### 7. Supplementary indication for *Aricept* for vascular dementia

With regard to the supplementary indication application for *Aricept* for the treatment of vascular dementia submitted to the FDA, Eisai Medical Research Inc. and Eisai Inc. received a non-approvable letter from the FDA on July 3, 2003 (U.S. ETD). Eisai will continue to work with the FDA toward our goal of bringing *ARICEPT* to patients with VaD. In the U.S., in 2002 approximately 3.4 million people were estimated to suffer from mild to moderate dementia with only 1.6 million patients or 46% of the total patient number being medically treated. Eisai Inc. aims to achieve its original target of 850 million dollars of sales in fiscal year 2006 through improving the public awareness level of Alzheimer's disease, increasing SOV through a reinforced sales force and introducing a rapidly dissolving tablet.

#### 8. Partial amendment of the marketing alliance agreement for *Maxalt*

Eisai and Kyorin Pharmaceutical Co., Ltd. reached an agreement on partial amendments of the joint marketing agreement concluded on February, 26 2003 for *Maxalt* (generic name: rizatriptan benzoate), and the companies executed the amended contract on July 30, 2003. The principal change from the former agreement is that the promotion of *Maxalt* will be performed solely by Eisai instead of by co-promotion of both companies. The import of *Maxalt* was approved in July, and the product will be launched during the first half of fiscal year 2003. With this agreement, Eisai believes its presence in neurology palTc (launched during the fr4 Tc (roTj 3.1644 Tc ( ) r644 Tc ( ) Tj 1 Tc (th7.4 g 2

acute pulmonary embolism. *Cleactor* is classified as an orphan drug (a medicine for a rare disease) therefore earlier evaluation is expected.

- u E5555 is an thrombin receptor for acute coronary syndrome. Eisai has started Ph. I clinical studies in May in the U.S.
- u Eisai has started Ph. I clinical studies for E2070, a selective sodium channel blocker, in July. Eisai will target neuropathic pain related with diabetes and herpetic neuralgia.

#### Growth of *Aricept*

- u Eisai is pursuing various potential indications for *Aricept*, which has been established as the gold standard treatment for Alzheimer's disease.
- u Vascular dementia is an area where *Aricept* is expected to have efficacy. Apart from the situation in the U.S. mentioned already, Eisai submitted a Variation to the Medicines Control Agency (now MHRA) which acted as the reference member state for the mutual recognition procedure in Europe. It is now in the final stages of evaluation.
- u Clinical studies of *Aricept* are ongoing for potential indications such as dementia related with Parkinson's disease, prevention of migraine, and severe Alzheimer's disease.

#### Growth of *Aciphex/Pariet*

- u Ph. III clinical studies for *Pariet* to eradicate *H.pylori* in combination with antibiotics are ongoing in Japan. The indication is already approved in the U.S. and Europe. By gaining the approval, Eisai aims to establish *Pariet* as a comprehensive treatment for acid related disease in Japan.

#### Progress of major pipeline and emerging new chemical entities

- u E5564, endotoxin antagonist for sepsis, is now in the mid-point of Ph. II clinical studies. Clinical studies for the prevention of coronary-artery bypass graft surgery prognosis, currently in Ph. II studies in the U.S., will start in Europe.
- u E2007, a novel oral AMPA receptor antagonist for multiple sclerosis, is in Ph. II. Eisai is conducting clinical studies for Parkinson's disease and epilepsy. In addition to the studies mainly conducted in Europe, Eisai will submit an IND and initiate studies in the U.S. in the second quarter of FY2003.
- u In oncology, one of our therapeutic focus areas, Ph. II clinical studies targeted for solid cancer are ongoing for E7070. Eisai will accelerate its studies for the early

attainment of an indication for breast cancer by mono-therapy. For E7389 Ph. I studies are currently being conducted by the U.S. National Cancer Institute (NCI), and Eisai is planning to start its own clinical studies.

- u Pre-clinical data of E7080, an angiogenesis inhibitor based on oral VEGF receptor tyrosinkinase inhibitor, was presented at the American Association of Cancer Research (AACR) in July. Eisai also presented pre-clinical data for E7070 and E7389 as well as for *pladienolide*, a novel anti-tumor agent derived from *streptomyces platensis Mer-11107*.

#### Progress of Japanese pipeline

- u Clinical studies for two anti-rheumatic agents, *Careram* (T-614) which has been co-developed with Toyama Chemical Co., Ltd. and adalimumab (D2E7) (Abbott U.S brand name: *Humira*®) which has been co-developed with Abbott Laboratories, have been conducted. Eisai will submit a marketing application for *Careram* during the second quarter.

#### [Forecasted Results for Fiscal Year 2003]

The forecasted figures of the interim and annual results for fiscal year 2003 announced this May have not changed.

The Company forecasts sales of 500 billion yen, an increase of 7% ~~from 462.5 billion~~

rheuTD j 157.225 phe t.6 Td-0.1107

Eisai utilizes “contribution to patients in the world and compliance with laws and ethics” as its corporate vision and seeks the vision driven operation under which research and development, manufacturing, and marketing are conducted.